NCT00793676

Brief Summary

The G protein-coupled receptors (GPCRs) are a family of proteins expressed at the cell membrane. They are composed of 380 members involved in the important functions of the organism and are privileged therapeutic targets.Their expression is highly modulated depending on the metabolic state of the cells, in particular in pathological situations.our study proposes to determine whether GPCR expression modulation could be used as a biomarker, either prognostic or diagnostic, of treatments.To do so , the investigators will determine the expression profile of the 380 human GPCRs in human blood cell samples in two chronic inflammatory pulmonary diseases : asthma and COPD (chronic obstructive pulmonary disease ) . These have opposed inflammatory infiltrates : asthma is associated with eosinophil and Th2 lymphocyte infiltration whereas COPD shows neutrophils and macrophages within the airways with a Th1 lymphocytic population. The GPCR signature (transcriptomic) will be determined on total white blood cells as well as on isolated mono- and poly-nuclear populations obtained from healthy subjects and patients selected at the asthma or COPD consultation. The expression profiling analysis will reveal sub-groups of GPCRs whose expression is modified in disease. The specificity of the variation of expression of these biomarker sub-populations will be determined, by a study recruiting a hundred patients and controls per disease on this restraint number of genes. The outcomes of the project will lead to establish GPCR "identity cards" for these chronic inflammatory diseases, which might therefore be used as diagnostic or prognostic biomarkers to follow the evolution of a disease or the efficacy of a given treatment. In addition, detailed analysis of the identified GPCRs will lead to propose new therapeutic targets for inflammatory diseases. This study has therefore the objective of validating GPCRs as potential biomarkers for inflammatory diseases.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
205

participants targeted

Target at P75+ for not_applicable asthma

Timeline
Completed

Started Sep 2008

Longer than P75 for not_applicable asthma

Geographic Reach
1 country

5 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2008

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

November 17, 2008

Completed
2 days until next milestone

First Posted

Study publicly available on registry

November 19, 2008

Completed
8.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2017

Completed
Last Updated

January 20, 2026

Status Verified

January 1, 2026

Enrollment Period

9 years

First QC Date

November 17, 2008

Last Update Submit

January 16, 2026

Conditions

COPDAsthma

Keywords

GPCR expressiontranscriptomicwhite blood cellsdiagnosticControl

Outcome Measures

Primary Outcomes (1)

  • differential expression of GPCRs

    1 day

Study Arms (3)

A= Asthma

OTHER
Other: spirometryOther: blood test

B= COPD

OTHER
Other: blood test

C= Control

OTHER
Other: blood test

Interventions

blood testOTHER
A= AsthmaB= COPDC= Control
spirometryOTHER
A= Asthma

Eligibility Criteria

Age18 Years - 85 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Asthma group
  • COPD group
  • Control group

You may not qualify if:

  • Patients with infection or inflammatory diseases

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (5)

Hospital

Colmar, 68024, France

Location

Pascal Chanez

Marseille, 13008, France

Location

University Hospital

Montpellier, 34295, France

Location

Antoine Magnan

Nantes, 44035, France

Location

University Hospital, Strasbourg, France

Strasbourg, 67000, France

Location

Related Publications (1)

  • Gras D, Martinez-Anton A, Bourdin A, Garulli C, de Senneville L, Vachier I, Vitte J, Chanez P. Human bronchial epithelium orchestrates dendritic cell activation in severe asthma. Eur Respir J. 2017 Mar 8;49(3):1602399. doi: 10.1183/13993003.02399-2016. Print 2017 Mar.

    PMID: 28275176RESULT

MeSH Terms

Conditions

AsthmaPulmonary Disease, Chronic ObstructiveDisease

Interventions

Hematologic Tests

Condition Hierarchy (Ancestors)

Bronchial DiseasesRespiratory Tract DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Clinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisInvestigative Techniques

Study Officials

  • Romain Kessler, MD

    University Hospital, Strasbourg, France

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
FACTORIAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 17, 2008

First Posted

November 19, 2008

Study Start

September 1, 2008

Primary Completion

September 1, 2017

Study Completion

September 1, 2017

Last Updated

January 20, 2026

Record last verified: 2026-01

Locations

FR(5)